Versant Vantage II GP-GP, LLC, 10% Owner at LENZ Therapeutics, Inc. (LENZ), sold 449,648 shares at $45.35 ($20.7M) on 2025-09-30, disclosed to the SEC on 2025-10-02.
Open-market sale of $20.7M LENZ by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.35 | 49,701 | $2.3M | 10.9% |
| 2 | $45.35 | 49,701 | $2.3M | 10.9% |
| 3 | $45.35 | 34,405 | $1.6M | 7.5% |
| 4 | $45.35 | 34,405 | $1.6M | 7.5% |
| 5 | $46.41 | 83,066 | $3.9M | 18.6% |
| 6 | $46.41 | 57,502 |
| $2.7M |
| 12.9% |
| 7 | $46.41 | 83,066 | $3.9M | 18.6% |
| 8 | $46.41 | 57,502 | $2.7M | 12.9% |
| 9 | $47.01 | 177 | $8K | 0.0% |
| 10 | $47.01 | 123 | $6K | 0.0% |
| Total | $46.01 avg | 449,648 | $20.7M | 100% |
| Filing → |
| GRPH | BUY | 2021-07-01 | $3.1M | — | Filing → |